SCHEMBL25815140

SCHEMBL25815140

CN1CCN(CCN(C)C(=O)c2ccc3[nH]c4c(c3c2)CCC4)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
LMNA P02545 6/20 0.49
KDM4E B2RXH2 6/20 0.49
MAPT P10636 6/20 0.49
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
POLB P06746 4/20 0.48
PARP1 P09874 2/20 0.47
GAA P10253 1/20 0.47
TP53 P04637 1/20 0.46
CASP1 P29466 1/20 0.46
MAPK1 P28482 2/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
F2 P00734 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25811835 0.98 LMNA (0.52) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL25811972 0.94 LMNA (0.51) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL25812002 0.92 KDM4E (0.54) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL25811968 0.92 LMNA (0.54) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL25811982 0.91 MAPT (0.53) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL25811720 0.90 KDR (0.49) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL25811965 0.88 MAPT (0.52) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL25813810 0.84 KDM4E (0.56) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL25815092 0.82 KDM4E (0.59) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL25811231 0.80 TP53 (0.66) MEN1KMT2ANPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 MEN1 3841/4885KMT2A 981/4885NPC1 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.